139 related articles for article (PubMed ID: 38279480)
1. Meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
Li L; Zhao Z; Li X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
3. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
4. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
[No Abstract] [Full Text] [Related]
5. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
6. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
D'Angelo CR; Hall A; Woo KM; Kim K; Longo W; Hematti P; Callander N; Kenkre VP; Mattison R; Juckett M
Leuk Res; 2020 Sep; 96():106419. PubMed ID: 32683127
[TBL] [Abstract][Full Text] [Related]
7. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
8. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
9. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
[TBL] [Abstract][Full Text] [Related]
10. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
[TBL] [Abstract][Full Text] [Related]
11. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract][Full Text] [Related]
12. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
13. Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis.
Zhang D; Chen J
Medicine (Baltimore); 2022 Sep; 101(37):e30644. PubMed ID: 36123842
[TBL] [Abstract][Full Text] [Related]
14. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Li L; Zhang R; Cao W; Bian Z; Qin Y; Guo R; Zhang S; Peng Y; Wan D; Ma W
Leuk Lymphoma; 2023 Dec; 64(13):2113-2122. PubMed ID: 37732615
[TBL] [Abstract][Full Text] [Related]
16. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X; Qi J; Li X; Zhou M; He J; Chu T; Han Y
Platelets; 2023 Dec; 34(1):2229905. PubMed ID: 37409458
[TBL] [Abstract][Full Text] [Related]
17. A 7-Day Decitabine-Included Conditioning Regimen Accelerated Donor Hematopoietic Engraftment while Reduced the Occurrence of Mucositis without Interfering with Prognosis.
Shi YY; Su L; Liu ZY; Cao YG; Chen X; Zhang RL; Liu QZ; Yao JF; Zhai WH; Ma QL; Jiang EL; Han MZ
Chemotherapy; 2023; 68(3):143-154. PubMed ID: 36990070
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang R; Lu X; Tang LV; Wang HF; Yan H; You Y; Zhong ZD; Shi W; Xia LH
Bone Marrow Transplant; 2022 Jul; 57(7):1063-1071. PubMed ID: 35459877
[TBL] [Abstract][Full Text] [Related]
19. Low-dose decitabine for refractory thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children: A pilot study.
Liu N; Zhao FY; Liang J; Shang LP; Xu XJ
Int Immunopharmacol; 2023 Feb; 115():109579. PubMed ID: 36577152
[TBL] [Abstract][Full Text] [Related]
20. [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies].
Fan LY; Hu SY; Xiao PF; Lu J; Li J; Yao YH; Ling J; Kong LJ; Liu H; Bian XN
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):679-682. PubMed ID: 30180454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
